
    
      Open-label first-in-human (FIH) phase 1 clinical trial assessing the safety, pharmacokinetics
      (PK), and clinical activity of orally (p.o.) administered APR-548 alone and in combination
      with azacitidine for the treatment of TP53-mutant myelodysplastic syndromes (MDS).
    
  